Disease · EFO_0006928

motion sickness

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. motion sickness. Diseases, record EFO_0006928. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0006928

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: motion sickness; Open Targets
Open Targets ID: EFO_0006928; Open Targets
Other names: travel sickness; Open Targets
NCI Thesaurus: C34824; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 8 drugs, from DailyMed; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SCOPOLAMINE	CHEMBL569713	Small molecule	Approval	DailyMed	7	5	5	Drugs and targets
MECLIZINE HYDROCHLORIDE	CHEMBL3989555	Small molecule	Approval	DailyMed	10	1	1	Drugs and targets
DIPHENHYDRAMINE HYDROCHLORIDE	CHEMBL1620	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
PROMETHAZINE HYDROCHLORIDE	CHEMBL1200750	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
TRADIPITANT	CHEMBL3544984	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
MECLIZINE	CHEMBL1623	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PROMETHAZINE	CHEMBL643	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RIZATRIPTAN	CHEMBL905	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH1	Histamine H1 receptor	5	Histamine H1 receptor antagonist	Approval	https://conductscience.org/library/genes/3269	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor M1	1	Muscarinic acetylcholine receptor M1 antagonist	Approval	https://conductscience.org/library/genes/1128	Drugs and targets
HTR1B	5-hydroxytryptamine receptor 1B	1	Serotonin 1b (5-HT1b) receptor agonist	Unknown	https://conductscience.org/library/genes/3351	Drugs and targets
HTR1D	5-hydroxytryptamine receptor 1D	1	Serotonin 1d (5-HT1d) receptor agonist	Unknown	https://conductscience.org/library/genes/3352	Drugs and targets
TACR1	Substance-P receptor	1	Neurokinin 1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/6869	Drugs and targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04327661	Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness	Phase 3	366	2024-12-11	Motion Sickness	TRADIPITANT	Its record names the disease	ClinicalTrials.gov
NCT05903924	Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness	Phase 3	316	2025-04-04	Motion Sickness	TRADIPITANT	Its record names the disease	ClinicalTrials.gov
NCT03772340	Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness	Phase 2	126	2025-05-09	Motion Sickness	TRADIPITANT	Its record names the disease	ClinicalTrials.gov
NCT02155309	Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray	Phase 2/3	63	2018-01-17	Motion Sickness	SCOPOLAMINE	Its record names the disease	ClinicalTrials.gov
NCT00360282	Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?	Not applicable	36	2014-12-08	Migraine	RIZATRIPTAN	Its record names the disease	ClinicalTrials.gov
NCT06138613	Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness	Phase 3	705		Motion Sickness	TRADIPITANT	Its record names the disease	ClinicalTrials.gov
NCT03920644	Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels	Phase 3	320		Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness	SCOPOLAMINE	Its record names the disease	ClinicalTrials.gov
NCT03986905	The Prevention and Treatment of Nausea Associated With Motion Sickness	Phase 3	300		Motion Sickness	SCOPOLAMINE	Its record names the disease	ClinicalTrials.gov
NCT05852730	Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance	Phase 2	80		Motion Sickness, Space, Motion Simulation, Parabolic Flight	MECLIZINE, PROMETHAZINE, SCOPOLAMINE	Its record names the disease	ClinicalTrials.gov
NCT04482985	Meclizine Plasma Levels in Responders and Non-responders	Phase 4	50		Seasickness, Meclizine	MECLIZINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tradipitant vs Placebo: deaths from any cause	0 of 63	0 of 63	126	NCT03772340	Trial comparisons
Tradipitant vs Placebo: serious adverse events	0 of 63	0 of 63	126	NCT03772340	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20862509	RESULT	1	PubMed
42150111	DERIVED	2	PubMed
40103934	DERIVED	1	PubMed
37042545	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0006928

GET https://conductscience.org/api/diseases/v1/EFO_0006928/drugs

API reference For AI assistants